New Jersey · 2026-2027 Regular Session · Bill
A 4550: Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols.
In committee Official data
- Introduced
- In committee
- Passed one chamber
- Passed both chambers
- Enacted
Last official action: ·Record last updated:
Plain-language summary
A 4550 is a bill introduced in the New Jersey House on March 10, 2026. According to its official title, it concerns: Requires health benefits coverage for buprenorphine and buprenorphine/naloxone for pain treatment without step therapy or fail-first protocols. Primary sponsor: Carol Murphy (Democratic). Most recent recorded action (March 10, 2026): Introduced, Referred to Assembly Financial Institutions and Insurance Committee.
Generated automatically from the official title, sponsor list, and status record only. It does not characterize the bill’s purpose or effects. How summaries are written
Sponsors
Sponsors by party (alphabetical): Democratic 1
| Name | Role | Party | Chamber | District |
|---|---|---|---|---|
| Carol Murphy | Primary sponsor | Democratic | House | 7 |
“Support” is shown only as formal sponsorship recorded by the legislature. Roll-call votes are available on the official bill page.
Recent official actions
- Introduced, Referred to Assembly Financial Institutions and Insurance Committee